BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35701334)

  • 1. A randomized double-blind single center study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention).
    Kreiberg M; Jørgensen N; Juul A; Lauritsen J; Oturai P; Helge JW; Christensen JF; Aksglaede L; Schauer T; Wagner T; Rosenvilde J; Grunwald E; Dehlendorff C; Daugaard G; Bandak M
    Clin Genitourin Cancer; 2022 Oct; 20(5):404-414. PubMed ID: 35701334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Testosterone Replacement Therapy on Quality of Life and Sexual Function in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency: Results From a Randomized Double-blind Trial.
    Højer EG; Kreiberg M; Dehlendorff C; Jørgensen N; Juul A; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Bandak M
    Clin Genitourin Cancer; 2022 Aug; 20(4):334-343. PubMed ID: 35514022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention).
    Bandak M; Jørgensen N; Juul A; Lauritsen J; Kreiberg M; Oturai PS; Helge JW; Daugaard G
    BMC Cancer; 2017 Jul; 17(1):461. PubMed ID: 28673265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 12-months testosterone replacement therapy on bone mineral density and markers of bone turnover in testicular cancer survivors - results from a randomized double-blind trial.
    Jørgensen PL; Kreiberg M; Jørgensen N; Juul A; Oturai PS; Dehlendorff C; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Medici CR; Jørgensen NR; Bandak M
    Acta Oncol; 2023 Jul; 62(7):689-695. PubMed ID: 37151105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like Factor 3, Basal and Human Chorionic Gonadotropin-Stimulated Testosterone as Biomarkers to Predict the Effect of Testosterone Replacement in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency.
    Medici C; Jørgensen N; Juul A; Albrethsen J; Kreiberg M; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Bandak M
    Clin Genitourin Cancer; 2024 Feb; 22(1):e106-e112.e4. PubMed ID: 37673783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testicular cancer survivors have shorter anogenital distance that is not increased by 1 year of testosterone replacement therapy.
    Priskorn L; Kreiberg M; Bandak M; Lauritsen J; Daugaard G; Petersen JH; Aksglaede L; Juul A; Jørgensen N
    Hum Reprod; 2021 Aug; 36(9):2443-2451. PubMed ID: 34223605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors.
    Bandak M; Jørgensen N; Juul A; Lauritsen J; Oturai PS; Mortensen J; Hojman P; Helge JW; Daugaard G
    Eur J Cancer; 2017 Oct; 84():9-17. PubMed ID: 28772110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy.
    Howell SJ; Radford JA; Adams JE; Smets EM; Warburton R; Shalet SM
    Clin Endocrinol (Oxf); 2001 Sep; 55(3):315-24. PubMed ID: 11589674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of Life in Long-Term Testicular Cancer Survivors With Compensated Leydig Cell Dysfunction.
    Skøtt JW; Lauritsen J; Kreiberg M; Daugaard G; Bandak M
    Clin Genitourin Cancer; 2019 Feb; 17(1):e65-e71. PubMed ID: 30293923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Changes in Serum Levels of Testosterone and Luteinizing Hormone in Testicular Cancer Patients after Orchiectomy Alone or Bleomycin, Etoposide, and Cisplatin.
    Bandak M; Jørgensen N; Juul A; Lauritsen J; Kier MGG; Mortensen MS; Daugaard G
    Eur Urol Focus; 2018 Jul; 4(4):591-598. PubMed ID: 28753832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preorchiectomy Leydig Cell Dysfunction in Patients With Testicular Cancer.
    Bandak M; Jørgensen N; Juul A; Lauritsen J; Gundgaard Kier MG; Mortensen MS; Daugaard G
    Clin Genitourin Cancer; 2017 Feb; 15(1):e37-e43. PubMed ID: 27524512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like factor 3, luteinizing hormone and testosterone in testicular cancer patients: effects of β-hCG and cancer treatment.
    Steggink LC; van Beek AP; Boer H; Meijer C; Lubberts S; Oosting SF; de Jong IJ; van Ginkel RJ; Lefrandt JD; Gietema JA; Nuver J
    Andrology; 2019 Jul; 7(4):441-448. PubMed ID: 30609309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial.
    Walsh JS; Marshall H; Smith IL; Greenfield DM; Swain J; Best E; Ashton J; Brown JM; Huddart R; Coleman RE; Snowden JA; Ross RJ
    PLoS Med; 2019 Nov; 16(11):e1002960. PubMed ID: 31714912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy.
    Magnussen LV; Glintborg D; Hermann P; Hougaard DM; Højlund K; Andersen M
    Diabetes Obes Metab; 2016 Oct; 18(10):980-9. PubMed ID: 27265844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
    Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
    JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the damage? Testicular germ cell tumour survivors deficient in testosterone at risk of metabolic syndrome and a need for medical intervention.
    Poniatowska G; Michalski W; Kucharz J; Jonska-Gmyrek J; Wieszczy P; Nietupski K; Demkow T; Dedecjus M; Sadowska M; Kalinowski T; Grochulska-Nalazek B; Nowatorska A; Stelmasiak P; Wiechno PJ
    Med Oncol; 2020 Aug; 37(9):82. PubMed ID: 32767179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone replacement therapy in older male subjective memory complainers: double-blind randomized crossover placebo-controlled clinical trial of physiological assessment and safety.
    Asih PR; Wahjoepramono EJ; Aniwiyanti V; Wijaya LK; de Ruyck K; Taddei K; Fuller SJ; Sohrabi H; Dhaliwal SS; Verdile G; Carruthers M; Martins RN
    CNS Neurol Disord Drug Targets; 2015; 14(5):576-86. PubMed ID: 25921747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer.
    Petersen PM; Skakkebaek NE; Vistisen K; Rørth M; Giwercman A
    J Clin Oncol; 1999 Mar; 17(3):941-7. PubMed ID: 10071288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone replacement therapy of opioid-induced male hypogonadism improved body composition but not pain perception: a double-blind, randomized, and placebo-controlled trial.
    Glintborg D; Vaegter HB; Christensen LL; Bendix E; Graven-Nielsen T; Andersen PG; Andersen M
    Eur J Endocrinol; 2020 Jun; 182(6):539-548. PubMed ID: 32213659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered bone status in unilateral testicular cancer survivors: Role of CYP2R1 and its luteinizing hormone-dependency.
    Foresta C; Selice R; De Toni L; Di Mambro A; Carraro U; Plebani M; Garolla A
    J Endocrinol Invest; 2013 Jun; 36(6):379-84. PubMed ID: 23047203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.